Please try another search
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical-Related business develops, manufactures, and sells injection and infusion products, artificial organ-related products, functional products, dialysis products, cell cultures, hospital products, diabetic products, and pharmaceuticals comprising generic and kit products; and manufactures medical equipment, including dialysis medical device products; and operates dialysis and training centers. The company’s Pharmaceutical-Related business engages in the contract manufacturing of pharmaceutical products with containers for combination products, including injectable kit products consigned by other pharmaceutical companies; and provides injectable, oral drugs products. In addition, its Pharma Packaging business offers pharmaceutical packaging containers and glass tubing, such as molded components for vials, syringes, rubber stoppers, and devices used to administer pharmaceuticals; and glass for thermos bottles, lighting and containers for combination products, glass equipment, as well glass for ampoules. Further, the company serves customers in Japan, the Americas, Europe, and rest of Asia. Nipro Corporation was founded in 1947 and is based in Settsu, Japan.
| Name | Age | Since | Title |
|---|---|---|---|
| Kawazu Hidehiko | - | 2022 | Independent Outside Director |
| Atsushi Yoneda | 58 | 2025 | Director, Production Technology Center & Director |
| Hideto Nakamura | 67 | 2009 | GM of General Affairs, HR Division & Governance and Director |
| Kenichi Nishida | 55 | 2012 | MD, Head of Pharmaceutical Business Division and Pharmaceutical Production & Director |
| Yasushi Oyama | 63 | 2015 | MD, Head of Vascular Business Division & Director |
| Yoshihiko Sano | 80 | 2000 | Chairman of Board & President |
| Takehito Yogo | 57 | 2006 | Senior MD, GM of Corporate Planning Div, Manager of Corporate Planning Dept, CSO & Director |
| Tsuyoshi Yamazaki | 57 | 2015 | Executive MD of PharmaPackaging, Head of International Bus. & Director |
| Kimihito Minoura | 53 | 2009 | MD, Head of Regenerative Medicine and Business Promotion, Business Management & Director |
| Kaname Sadahiro | 69 | 2018 | GM of Intn. Business, Domestic Business Division Product Dev., Technical Sales & Director |
| Hattori Toshiaki | 71 | 2022 | Independent Outside Director |
| Yoshitaka Akikuni | 72 | 2023 | Outside Statutory Auditor |
| Shigeru Yanagase | 78 | 2023 | Outside Statutory Auditor |
| Imaizumi Yasuhiko | 69 | 2024 | Independent Outside Director |
| Hideyuki Nishisako | 45 | 2025 | Director of Hua-Ma Packaging Business Division & Director |
| Hideyuki Nishisako | - | 2025 | Director |
| Takayuki Nomiya | 82 | 2008 | Chairman of Audit & Supervisory Board |
| Yoshiko Tanaka | 76 | 2014 | Independent Lead Outside Director |
| Toshinobu Morimoto | - | 2025 | Audit & Supervisory Board |
| Taku Nikaido | 62 | 2025 | Director & Head of Domestic Business Division |
| Goichi Miyazumi | 56 | 2025 | Director & GM of International Business Division |
| Shimamori Yoshiko | 78 | 2021 | Independent Outside Director |
| Kushida Yuka | 62 | 2024 | Independent Outside Director |
| Yoshimori Toshikazu | 74 | 2024 | Independent Outside Director |
| Yoneda Atsushi | - | 2025 | Director |
| Taku Nikaido | - | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review